Farnesoid X Receptor Agonism, Acetyl‐Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model

Autor: Berangere Gapp, Marie Jourdain, Pauline Bringer, Benjamin Kueng, Delphine Weber, Arnaud Osmont, Stefan Zurbruegg, Judith Knehr, Rocco Falchetto, Guglielmo Roma, William Dietrich, Reginald Valdez, Nicolau Beckmann, Florian Nigsch, Arun J. Sanyal, Iwona Ksiazek

Publikováno v: Hepatology Communications, Vol 4, Iss 1, Pp 109-125 (2020)

A promising approach for the treatment of nonalcoholic steatohepatitis (NASH) is the inhibition of enhanced hepatic de novo lipogenesis (DNL), which is the synthesis of fatty acids from nonlipid sources. This study assesses three approaches to DNL su

Externí odkaz: https://doaj.org/article/f53881fedaa04196a137467b2582c5f6

Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other Rare Diseases: A Patient-Initiated EQ-5D Feasibility Study

Autor: Jasmin Barman-Aksözen, Anna-Elisabeth Minder, Francesca Granata, Mårten Pettersson, Cornelia Dechant, Mehmet Hakan Aksözen, Rocco Falchetto

Publikováno v: International Journal of Environmental Research and Public Health; Volume 20; Issue 7; Pages: 5296

Erythropoietic protoporphyria (EPP) is an ultra-rare inborn error of metabolism characterised by painful phototoxic burn injuries after short exposure times to visible light. Patients with EPP are highly adapted to their condition which makes the qua

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68371d6dbba67e89820c8a17655f4d66

S1372 Changes in Acute Hepatic Porphyria Health Impacts Since Initial Diagnosis: Results From the Porphyria Worldwide Patient Experience Research (POWER) Study

Autor: Stephen L. Meninger, Danielle Nance, Desiree Lyon, Sean R. Hegarty, Rocco Falchetto, Jasmin Barman-Aksözen, Tarek Mnif, Stephen Lombardelli, Amy Dickey

Publikováno v: American Journal of Gastroenterology. 117:e986-e986

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dbddc00aa4671ef57b6d0f11b33430ae
https://doi.org/10.14309/01.ajg.0000862128.47486.44

Farnesoid X Receptor Agonism, Acetyl‐Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model

Autor: Florian Nigsch, Rocco Falchetto, Nicolau Beckmann, Guglielmo Roma, Iwona Ksiazek, William F. Dietrich, Marie Jourdain, Delphine Weber, Pauline Bringer, Arun J. Sanyal, Berangere Gapp, Benjamin Kueng, Stefan Zurbruegg, Judith Knehr, Reginald Valdez, Arnaud Osmont

Publikováno v: Hepatology Communications, Vol 4, Iss 1, Pp 109-125 (2020)

A promising approach for the treatment of nonalcoholic steatohepatitis (NASH) is the inhibition of enhanced hepatic de novo lipogenesis (DNL), which is the synthesis of fatty acids from nonlipid sources. This study assesses three approaches to DNL su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::477d9ff925e31520b4d6db746c31a3e8
https://doi.org/10.1002/hep4.1443

Patient preferences in the medical product lifecycle

Autor: Michael Drummond, Nigel S. Cook, Esther W. de Bekker-Grob, Fern Terris-Prestholt, Hans L. Hillege, Jennifer A. Whitty, Rocco Falchetto

Publikováno v: Patient-Patient: centered outcomes research, 13, 7-10. ADIS INT LTD
The patient: Patient-Centered Outcomes Research. Springer Science+Business Media

There is an emerging consensus that evidence on patients’ perspectives provides crucial guidance for decision making throughout the medical product lifecycle (MPLC). Consid-ering the patient voice has become increasingly important for developers of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a487f8f1616e9d4d33e484230302576e
https://ueaeprints.uea.ac.uk/id/eprint/73501/